BIOGEN INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was -$1.60M.
- BIOGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was -$1.80M.
- BIOGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was -$62.60M.
- BIOGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was -$2.70M.
- BIOGEN INC. stock issued during period, value, stock options exercised for fiscal 2020 was -$53.70M.
- BIOGEN INC. stock issued during period, value, stock options exercised for fiscal 2019 was -$53.80M.
- BIOGEN INC. stock issued during period, value, stock options exercised for fiscal 2018 was -$43.80M, a 195.63% decline from fiscal 2017.
- BIOGEN INC. stock issued during period, value, stock options exercised for fiscal 2017 was $45.80M, a 12.09% decline from fiscal 2016.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-09-30 | -$1.60M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | -$1.80M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | -$62.60M 10-Q · filed 2024-04-24 | |
| 2023-09-30 | -$2.70M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | -$3.80M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | -$80.20M 10-Q · filed 2024-04-24 | |
| 2022-09-30 | -$2.80M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$700.00K 10-Q · filed 2023-07-25 | |
| 2022-03-31 | -$39.70M 10-Q · filed 2023-04-25 | |
| 2021-09-30 | -$5.00M 10-Q · filed 2022-10-25 | -$56.00M derived: sum of 4 quarters · filed 2022-10-25 |
| 2021-06-30 | -$800.00K 10-Q · filed 2022-07-20 | -$53.30M derived: sum of 4 quarters · filed 2022-07-20 |
| 2021-03-31 | -$46.80M 10-Q · filed 2022-05-03 | -$52.80M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | -$3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$53.70M 10-K · filed 2021-02-03 |
| 2020-09-30 | -$2.30M 10-Q · filed 2021-10-20 | -$53.50M derived: sum of 4 quarters · filed 2021-10-20 |
| 2020-06-30 | -$300.00K 10-Q · filed 2021-07-22 | -$51.90M derived: sum of 4 quarters · filed 2021-07-22 |
| 2020-03-31 | -$47.80M 10-Q · filed 2021-04-22 | -$52.70M derived: sum of 4 quarters · filed 2021-04-22 |
| 2019-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$53.80M 10-K · filed 2021-02-03 |
| 2019-09-30 | -$700.00K 10-Q · filed 2020-10-21 | -$36.60M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | -$1.10M 10-Q · filed 2020-07-22 | -$34.80M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $48.90M 10-Q · filed 2020-04-23 | -$32.20M derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | -$83.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$43.80M 10-K · filed 2021-02-03 |
| 2018-09-30 | $1.10M 10-Q · filed 2019-10-22 | |
| 2018-06-30 | $1.50M 10-Q · filed 2019-07-24 | |
| 2018-03-31 | $37.80M 10-Q · filed 2019-04-24 | |
| 2017-12-31 | $45.80M 10-K · filed 2020-02-06 | |
| 2016-12-31 | $52.10M 10-K · filed 2019-02-06 | |
| 2015-12-31 | $125.10M 10-K · filed 2018-02-01 | |
| 2014-12-31 | $140.30M 10-K · filed 2017-02-02 | |
| 2013-12-31 | $89.70M 10-K · filed 2016-02-03 | |
| 2012-12-31 | $71.36M 10-K · filed 2015-02-04 | |
| 2011-12-31 | -$50.95M 10-K · filed 2014-02-06 | |
| 2010-12-31 | -$54.84M 10-K · filed 2013-02-05 | |
| 2009-12-31 | -$43.30M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |